Oncology Institute Q1 revenue rises on specialty pharmacy growth, reaffirms 2026 revenue guidance

Oncology Institute

07/05/2026 22:05

Overview

US oncology care provider's Q1 revenue rose 41% yr/yr, driven by specialty pharmacy growth

Gross profit for Q1 increased 35% yr/yr; net loss narrowed from prior year

Company reaffirmed 2026 revenue and adjusted EBITDA guidance, raised free cash flow outlook

Outlook

Company reaffirms 2026 revenue guidance at $630 mln to $650 mln

Company raises 2026 free cash flow outlook to $5 mln to $15 mln

Company expects Q2 2026 adjusted EBITDA of $(1) mln to $1 mln

Result Drivers

SPECIALTY PHARMACY GROWTH - Record Part D fills drove specialty pharmacy revenue up 78% yr/yr, reflecting higher membership volume and improved attachment rates

CAPITATED REVENUE - Growth in capitated revenue contributed to overall revenue increase and profitability in Florida, per CEO Daniel Virnich

COST SAVINGS INITIATIVES - Participation in CMS Enhancing Oncology Model led to $2 mln in Medicare savings while maintaining care quality

Company press release: ID:nGNXbvB2g0

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.02
Q1 Net Income
-$2.50 mln
Q1 Gross Profit
$23.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Oncology Institute Inc is $7.50, about 97.4% above its May 6 closing price of $3.80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)